Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Gene Silencing/Gene Editing » Qiagen Licenses Novartis SiRNA Selection Algorithm; Publication of Details in the Works

Qiagen Licenses Novartis SiRNA Selection Algorithm; Publication of Details in the Works

Dec 19, 2003
Premium

Qiagen announced this week that it has taken a worldwide license to a novel siRNA selection algorithm designed by Swiss drug maker Novartis.

According to Eric Lader, associate director of business development at Qiagen, Novartis designed the algorithm using a collection of about 3,000 randomly designed synthetic siRNAs against 34 targets provided by Qiagen. The randomness of the siRNAs, which allowed them to be chosen in an unbiased manner, is what makes Novartis’ algorithm different from methods others use to select siRNAs, he added.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Boosting Viral Surveillance

The Financial Times reports the US bolstering its ability to track SARS-CoV-2 alterations.

California Strain

The New York Times reports that Cedars-Sinai researchers have uncovered a new strain of SARS-CoV-2 in Southern California.

Nucleic Acids Research Studies on Pan-Cancer MiRNA Biogenesis Mutations, Skeletal Methylation, More

In Nucleic Acids Research this week: pan-cancer atlas focus on miRNA biogenesis mutations, methylation analysis of pig skeletal muscles, and more.

Lander Nominated for Science Advisor

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.

Jan
26
Featured Webinar

Panel Discussion: Genotyping by Sequencing for Novel SNP Discovery with Less Common Genomes

Sponsored by
LGC, Biosearch Technologies

Reduced representation next-generation sequencing (NGS) methods are driving understanding of both physical and structural variation in all species.

Feb
18
Featured Webinar

Single-Cell Multiomics to Elucidate Immune Alterations in the Human Tumor Microenvironment

Sponsored by
BD

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

What's Popular?

In Gene Silencing/Gene Editing

  1. Mammoth Biosciences Taking Lead Role in DARPA-Funded Development of Pathogen Detection Tech

    Premium

  2. DARPA Awards $36.7M to Six Organizations for Gene Editing-Based Dx, Biosurveillance Tech

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.